摘要
目的探讨siRNA干扰大鼠含I型血小板结合蛋白基序的解聚蛋白样金属蛋白酶2（ADAMTS2）基因后对大鼠肝星状细胞（HSC）生物学特性的影响及其机制，评估ADAMTS2基因作为一种新的靶向基因在抗肝纤维化治疗中的应用前景。方法设计并化学合成3对针对大鼠ADAMTs2mRNA2237、2597及690位点的siRNAs。用筛选出的抑制效率最高的siRNA体外转染HSC—T6，应用实时PCR、Westernblot及MTT等方法研究沉默ADAMTS2基因对大鼠HSC活化、增殖等生物学特性及对基因ADAMTS2、α—SMA、COLlal、COL（I）、TGF-β1、MMP-2和TIMP-3表达的影响。结果在相同注射剂量（50nmol／L）及时间（48h）下，2237位点的siRNA—ADAMTS2具有最高的抑制效率；能显著抑制ADAMTS2基因mRNA和蛋白表达（抑制率80％以上）；显著抑制COL（I）、α—SMA和TGF—β1在HSC中的表达。HSC的增殖能力显著降低。结论化学合成的siRNA—ADAMTS2干扰载体能有效抑制ADAMTS2基因在大鼠HSC-T6细胞系中的表达，抑制HSC的活化和增殖，同时显著降低COL（I）、α—SMA和TGF-β1的表达，具有潜在的阻止甚至逆转肝纤维化的作用。ADAMTs2可能是抗肝纤维化治疗的有效靶位，抑制ADAMTS2在肝脏的表达可能是一种有效的抗肝纤维化治疗策略。
Objective To explore the preventive and therapeutic role of silencing type I rat platelet-binding protein motifs depolymerization protein-like metalloproteinase 2 （ADAMTS2） by siRNA on experimental liver fibrosis in vitro. By studying the mechanism of siRNA silencing of ADAMTS2, we also aim to evaluate the feasibility of ADAMTS2 as a target for anti-liver fibrosis therapy. Methods Three pairs of siRNAs targeting ADAMTS2 mRNA 2237, 2597 and 690 targets were designed and synthesized by utilizing RNA design software. The most effective siRNA was chosen to transfect HSC-T6 cell line to test the tendency of hepatic stellate cell （HSC） activation and ex- pression of ADAMTS2, COLlal, COL（I）,α-SMA, TGF-β1, MMP-2 and TIMP-3. These were quantified using real time-PCR, Western blotting, and MTT assays. Results Of the same dosage and time of injection, siRNA 2237 inhibited ADAMTS2 gene expression significantly more than other siRNAs, siRNA-ADAMTS2 2237 markedly inhibited ADAMTS2 gene and protein expression of HSC- T6 with more than 80% efficiency. Conversely, siRNA-ADAMTS2 2237 markedly reduced the gene and protein expressions of COL（I）, α-SMA and TGF-β1 on HSC-T6 and inhibited the proliferation of HSC. Conclusions siRNA-ADAMTS2 2237 could effectively knockdown the gene and protein expression of ADAMTS2 in HSC-T6 cell lines. Silencing ADAMTS2 by siRNA significantly inhibited the activation, proliferation of HSC and the gene and protein expressions of COL（I）, α-SMA, and TGF- β1, and it may have a potential anti-fibrotic effect. ADAMTS2 might be an efficient target for anti- fibrotic therapy.
出处
《中华肝胆外科杂志》
CAS
CSCD
北大核心
2012年第3期205-210,共6页
Chinese Journal of Hepatobiliary Surgery
基金
基金项目：上海交通大学医学院附属仁济医院重点学科项目（RJ4101310）
